新辅助化疗后胃癌开放与微创全胃切除术的三年生存及淋巴结转移分布:欧洲随机临床试验结果
该研究为STOMACH随机临床试验的回顾性分析,纳入96例新辅助化疗后的进展期胃癌患者,随机分为开放全胃切除术(OTG,49例)与微创全胃切除术(MITG,47例)。两组三年生存率分别为57.1%与46.8%(P=0.186),淋巴结检出数及D2淋巴结清扫完成率无差异,但病理科评估的D2依从性均较低(OTG 30%,MITG 36%),且MITG组第2站淋巴结转移比例更高(43.5% vs 19.6%,P=0.024)。
要点
- 开放与微创全胃切除术在新辅助化疗后胃癌中三年生存无显著差异。
- 两组淋巴结检出数和D2清扫完成率无差异,但病理科评估的D2依从性均较低。
- MITG组第2站(7-12站)淋巴结转移比例显著高于OTG组。
核心结论
- 开放与微创全胃切除术在新辅助化疗后的进展期胃癌患者中三年生存无显著差异。
- 两组淋巴结检出数和淋巴结清扫类型无差异,但病理科评估的D2淋巴结清扫依从性明显较低。
- 微创组第2站淋巴结转移比例显著高于开放组。
研究设计与样本
- 患者随机分为开放全胃切除术组(49例)和微创全胃切除术组(47例)。
- 分析指标包括三年生存率、淋巴结检出数、淋巴结清扫完整性及分布模式。
主要发现
- 三年生存率开放组为57.1%,微创组为46.8%(P=0.186)。
- 每例患者平均检出淋巴结数开放组为44.3±16.7枚,微创组为40.7±16.3枚(P=0.209)。
- 外科医生报告的D2淋巴结清扫完成率开放组为71.4%,微创组为74.5%;病理科评估的依从性开放组为30%,微创组为36%。
- 第2站(7-12站)淋巴结转移开放组为19.6%,微创组为43.5%(P=0.024)。
临床怎么用
- 在新辅助化疗后的进展期胃癌中,开放与微创全胃切除术的三年生存和淋巴结检出数无显著差异。
- 需关注病理科评估的D2淋巴结清扫依从性较低的问题,可能影响分期准确性。
- 微创全胃切除术中第2站淋巴结转移比例较高,应确保该站淋巴结的彻底清扫。
局限性
- 本研究为随机临床试验的回顾性分析,样本量较小(共96例)。
- 病理科评估的D2依从性明显低于外科医生报告,可能存在评估偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adequate lymphadenectomy is an important step in gastrectomy for cancer, with a modified D2 lymphadenectomy being recommended for advanced gastric cancers. When assessing a novel technique for the treatment of gastric cancer, lymphadenectomy should be non-inferior. The aim of this study was to assess completeness of lymphadenectomy and distribution patterns between open total gastrectomy (OTG) and minimally invasive total gastrectomy (MITG) in the era of peri-operative chemotherapy. METHODS: This is a retrospective analysis of the STOMACH trial, a randomized clinical trial in thirteen hospitals in Europe. Patients were randomized between OTG and MITG for advanced gastric cancer after neoadjuvant chemotherapy. Three-year survival, number of resected lymph nodes, completeness of lymphadenectomy, and distribution patterns were examined. RESULTS: A total of 96 patients were included in this trial and randomized between OTG (49 patients) and MITG (47 patients). No difference in 3-year survival was observed, this was 57.1% in OTG group versus 46.8% in MITG group (P = 0.186). The mean number of examined lymph nodes per patient was 44.3 ± 16.7 in the OTG group and 40.7 ± 16.3 in the MITG group (P = 0.209). D2 lymphadenectomy of 71.4% in the OTG group and 74.5% in the MITG group was performed according to the surgeons; according to the pathologist compliance to D2 lymphadenectomy was 30% in the OTG group and 36% in the MITG group. Tier 2 lymph node metastases (stations 7-12) were observed in 19.6% in the OTG group versus 43.5% in the MITG group (P = 0.024). CONCLUSION: No difference in 3-year survival was observed between open and minimally invasive gastrectomy. No differences were observed for lymph node yield and type of lymphadenectomy. Adherence to D2 lymphadenectomy reported by the pathologist was markedly low.
引用
- van der Wielen N, Daams F, Rosati R, et al. Three-year survival and distribution of lymph node metastases in gastric cancer following neoadjuvant chemotherapy: results from a European randomized clinical trial. Surg Endosc. 2023. PMID: 37468751. doi:10.1007/s00464-023-10278-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。